25 XP   0   0   10

GenMont Biotech Inc
Buy, Hold or Sell?

Let's analyse Genmont together

PenkeI guess you are interested in GenMont Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GenMont Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GenMont Biotech Inc

I send you an email if I find something interesting about GenMont Biotech Inc.

Quick analysis of Genmont (30 sec.)










What can you expect buying and holding a share of Genmont? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
37.5%

What is your share worth?

Current worth
NT$16.75
Expected worth in 1 year
NT$16.19
How sure are you?
57.5%

+ What do you gain per year?

Total Gains per Share
NT$-0.56
Return On Investment
-2.5%

For what price can you sell your share?

Current Price per Share
NT$22.10
Expected price per share
NT$21.40 - NT$23.30
How sure are you?
50%

1. Valuation of Genmont (5 min.)




Live pricePrice per Share (EOD)

NT$22.10

Intrinsic Value Per Share

NT$-24.33 - NT$14.40

Total Value Per Share

NT$-7.58 - NT$31.15

2. Growth of Genmont (5 min.)




Is Genmont growing?

Current yearPrevious yearGrowGrow %
How rich?$44.4m$46.4m-$2m-4.6%

How much money is Genmont making?

Current yearPrevious yearGrowGrow %
Making money$253.2k$437.3k-$184.1k-72.7%
Net Profit Margin10.5%15.4%--

How much money comes from the company's main activities?

3. Financial Health of Genmont (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#486 / 1010

Most Revenue
#425 / 1010

Most Profit
#158 / 1010

Most Efficient
#108 / 1010

What can you expect buying and holding a share of Genmont? (5 min.)

Welcome investor! Genmont's management wants to use your money to grow the business. In return you get a share of Genmont.

What can you expect buying and holding a share of Genmont?

First you should know what it really means to hold a share of Genmont. And how you can make/lose money.

Speculation

The Price per Share of Genmont is NT$22.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Genmont.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Genmont, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$16.75. Based on the TTM, the Book Value Change Per Share is NT$-0.14 per quarter. Based on the YOY, the Book Value Change Per Share is NT$-0.08 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Genmont.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.000.0%0.000.0%0.010.0%0.010.0%0.000.0%
Usd Book Value Change Per Share-0.010.0%0.000.0%0.000.0%0.000.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.030.1%0.020.1%0.010.1%
Usd Total Gains Per Share-0.010.0%0.000.0%0.020.1%0.020.1%0.020.1%
Usd Price Per Share0.76-0.75-0.76-0.75-0.82-
Price to Earnings Ratio-265.12-9.02-43.51-26.02-14.25-
Price-to-Total Gains Ratio-108.07--47.87-107.23-11.67--28.67-
Price to Book Ratio1.47-1.46-1.42-1.44-1.75-
Price-to-Total Gains Ratio-108.07--47.87-107.23-11.67--28.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.67847
Number of shares1473
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.02
Gains per Quarter (1473 shares)-6.2928.39
Gains per Year (1473 shares)-25.14113.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-25-35121-7104
20-50-60242-15218
30-75-85363-22332
40-101-110484-30446
50-126-135605-37560
60-151-160726-45674
70-176-185847-52788
80-201-210968-60902
90-226-2351089-671016
100-251-2601210-751130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%18.02.00.090.0%25.05.010.062.5%44.05.013.071.0%
Book Value Change Per Share1.03.00.025.0%7.05.00.058.3%11.09.00.055.0%20.020.00.050.0%32.030.00.051.6%
Dividend per Share0.00.04.00.0%7.00.05.058.3%14.00.06.070.0%15.00.025.037.5%23.00.039.037.1%
Total Gains per Share1.03.00.025.0%8.04.00.066.7%14.06.00.070.0%23.017.00.057.5%37.025.00.059.7%

Fundamentals of Genmont

About GenMont Biotech Inc

GenMont Biotech Incorporation engages in the research, development, manufacture, and sale of functional probiotic supplements in Taiwan. The company offers functional probiotics raw materials, capsules, powder, tablets, and liquid products; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.

Fundamental data was last updated by Penke on 2024-04-16 19:11:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of GenMont Biotech Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genmont earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • A Net Profit Margin of -2.7% means that NT$-0.03 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GenMont Biotech Inc:

  • The MRQ is -2.7%. The company is making a loss. -1
  • The TTM is 10.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-2.7%TTM10.5%-13.3%
TTM10.5%YOY15.4%-4.9%
TTM10.5%5Y17.3%-6.8%
5Y17.3%10Y8.9%+8.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.7%-200.1%+197.4%
TTM10.5%-216.8%+227.3%
YOY15.4%-288.3%+303.7%
5Y17.3%-449.1%+466.4%
10Y8.9%-605.5%+614.4%
1.1.2. Return on Assets

Shows how efficient Genmont is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • -0.1% Return on Assets means that Genmont generated NT$0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GenMont Biotech Inc:

  • The MRQ is -0.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.5%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.1%TTM0.5%-0.6%
TTM0.5%YOY0.8%-0.3%
TTM0.5%5Y1.0%-0.5%
5Y1.0%10Y0.4%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.1%-13.3%+13.2%
TTM0.5%-12.8%+13.3%
YOY0.8%-11.7%+12.5%
5Y1.0%-13.9%+14.9%
10Y0.4%-15.7%+16.1%
1.1.3. Return on Equity

Shows how efficient Genmont is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • -0.2% Return on Equity means Genmont generated NT$0.00 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GenMont Biotech Inc:

  • The MRQ is -0.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM0.6%-0.8%
TTM0.6%YOY1.0%-0.4%
TTM0.6%5Y1.2%-0.5%
5Y1.2%10Y0.5%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.2%-16.9%+16.7%
TTM0.6%-16.1%+16.7%
YOY1.0%-15.1%+16.1%
5Y1.2%-19.3%+20.5%
10Y0.5%-20.2%+20.7%

1.2. Operating Efficiency of GenMont Biotech Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genmont is operating .

  • Measures how much profit Genmont makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GenMont Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.1%-2.1%
TTM2.1%YOY15.9%-13.8%
TTM2.1%5Y19.3%-17.1%
5Y19.3%10Y12.6%+6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM2.1%-232.5%+234.6%
YOY15.9%-298.2%+314.1%
5Y19.3%-492.1%+511.4%
10Y12.6%-632.4%+645.0%
1.2.2. Operating Ratio

Measures how efficient Genmont is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.29 means that the operating costs are NT$1.29 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of GenMont Biotech Inc:

  • The MRQ is 1.291. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.311. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.291TTM1.311-0.020
TTM1.311YOY1.154+0.157
TTM1.3115Y1.141+0.170
5Y1.14110Y0.920+0.221
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2913.231-1.940
TTM1.3113.310-1.999
YOY1.1543.890-2.736
5Y1.1415.739-4.598
10Y0.9207.876-6.956

1.3. Liquidity of GenMont Biotech Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genmont is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.18 means the company has NT$3.18 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of GenMont Biotech Inc:

  • The MRQ is 3.180. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.122. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.180TTM3.122+0.058
TTM3.122YOY3.611-0.489
TTM3.1225Y5.390-2.268
5Y5.39010Y4.236+1.154
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1803.890-0.710
TTM3.1224.173-1.051
YOY3.6115.344-1.733
5Y5.3906.126-0.736
10Y4.2366.448-2.212
1.3.2. Quick Ratio

Measures if Genmont is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • A Quick Ratio of 2.12 means the company can pay off NT$2.12 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GenMont Biotech Inc:

  • The MRQ is 2.124. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.995. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.124TTM1.995+0.129
TTM1.995YOY2.157-0.162
TTM1.9955Y2.987-0.992
5Y2.98710Y2.447+0.540
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1243.514-1.390
TTM1.9953.998-2.003
YOY2.1575.380-3.223
5Y2.9876.105-3.118
10Y2.4476.404-3.957

1.4. Solvency of GenMont Biotech Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genmont assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genmont to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Genmont assets are financed with 12.3% credit (debt) and the remaining percentage (100% - 12.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GenMont Biotech Inc:

  • The MRQ is 0.123. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.127. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.123TTM0.127-0.003
TTM0.127YOY0.108+0.018
TTM0.1275Y0.101+0.026
5Y0.10110Y0.132-0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1230.339-0.216
TTM0.1270.336-0.209
YOY0.1080.271-0.163
5Y0.1010.366-0.265
10Y0.1320.389-0.257
1.4.2. Debt to Equity Ratio

Measures if Genmont is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genmont to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.5% means that company has NT$0.16 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GenMont Biotech Inc:

  • The MRQ is 0.155. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.161. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.161-0.005
TTM0.161YOY0.135+0.026
TTM0.1615Y0.124+0.037
5Y0.12410Y0.232-0.109
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1550.388-0.233
TTM0.1610.402-0.241
YOY0.1350.335-0.200
5Y0.1240.426-0.302
10Y0.2320.461-0.229

2. Market Valuation of GenMont Biotech Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Genmont generates.

  • Above 15 is considered overpriced but always compare Genmont to the Biotechnology industry mean.
  • A PE ratio of -265.12 means the investor is paying NT$-265.12 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GenMont Biotech Inc:

  • The EOD is -237.209. Based on the earnings, the company is expensive. -2
  • The MRQ is -265.116. Based on the earnings, the company is expensive. -2
  • The TTM is 9.022. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-237.209MRQ-265.116+27.907
MRQ-265.116TTM9.022-274.137
TTM9.022YOY43.506-34.485
TTM9.0225Y26.024-17.003
5Y26.02410Y14.248+11.776
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-237.209-2.264-234.945
MRQ-265.116-2.629-262.487
TTM9.022-2.680+11.702
YOY43.506-4.145+47.651
5Y26.024-6.257+32.281
10Y14.248-6.254+20.502
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GenMont Biotech Inc:

  • The EOD is 17.084. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 19.094. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 17.003. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD17.084MRQ19.094-2.010
MRQ19.094TTM17.003+2.091
TTM17.003YOY57.285-40.282
TTM17.0035Y12.121+4.882
5Y12.12110Y6.350+5.772
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD17.084-2.973+20.057
MRQ19.094-3.333+22.427
TTM17.003-3.553+20.556
YOY57.285-5.605+62.890
5Y12.121-8.376+20.497
10Y6.350-8.865+15.215
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genmont is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.47 means the investor is paying NT$1.47 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of GenMont Biotech Inc:

  • The EOD is 1.319. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.475. Based on the equity, the company is underpriced. +1
  • The TTM is 1.457. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.319MRQ1.475-0.155
MRQ1.475TTM1.457+0.018
TTM1.457YOY1.417+0.039
TTM1.4575Y1.443+0.014
5Y1.44310Y1.745-0.303
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3191.896-0.577
MRQ1.4752.115-0.640
TTM1.4572.093-0.636
YOY1.4172.884-1.467
5Y1.4433.542-2.099
10Y1.7453.916-2.171
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GenMont Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.229-0.139-39%-0.079-66%-0.041-82%0.169-235%
Book Value Per Share--16.75116.724+0%17.500-4%17.022-2%16.281+3%
Current Ratio--3.1803.122+2%3.611-12%5.390-41%4.236-25%
Debt To Asset Ratio--0.1230.127-2%0.108+14%0.101+22%0.132-6%
Debt To Equity Ratio--0.1550.161-3%0.135+15%0.124+25%0.232-33%
Dividend Per Share----0%0.824-100%0.669-100%0.372-100%
Eps---0.0230.088-126%0.165-114%0.183-113%0.091-126%
Free Cash Flow Per Share--0.323-0.003+101%0.194+67%-0.156+148%-0.218+168%
Free Cash Flow To Equity Per Share--0.323-0.005+102%-0.070+122%-0.348+208%-0.294+191%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.750+33%
Intrinsic Value_10Y_max--14.399--------
Intrinsic Value_10Y_min---24.333--------
Intrinsic Value_1Y_max--0.409--------
Intrinsic Value_1Y_min---1.147--------
Intrinsic Value_3Y_max--2.017--------
Intrinsic Value_3Y_min---4.585--------
Intrinsic Value_5Y_max--4.575--------
Intrinsic Value_5Y_min---9.245--------
Market Cap1911901940.000-12%2136831580.0002106552590.000+1%2144401327.5000%2140680488.5000%2323266447.876-8%
Net Profit Margin---0.0270.105-126%0.154-118%0.173-116%0.089-131%
Operating Margin---0.021-100%0.159-100%0.193-100%0.126-100%
Operating Ratio--1.2911.311-2%1.154+12%1.141+13%0.920+40%
Pb Ratio1.319-12%1.4751.457+1%1.417+4%1.443+2%1.745-16%
Pe Ratio-237.209+11%-265.1169.022-3039%43.506-709%26.024-1119%14.248-1961%
Price Per Share22.100-12%24.70024.350+1%24.7880%24.535+1%26.587-7%
Price To Free Cash Flow Ratio17.084-12%19.09417.003+12%57.285-67%12.121+58%6.350+201%
Price To Total Gains Ratio-96.693+11%-108.068-47.870-56%107.229-201%11.667-1026%-28.666-73%
Quick Ratio--2.1241.995+6%2.157-2%2.987-29%2.447-13%
Return On Assets---0.0010.005-124%0.008-115%0.010-113%0.004-128%
Return On Equity---0.0020.006-125%0.010-115%0.012-113%0.005-128%
Total Gains Per Share---0.229-0.139-39%0.745-131%0.628-136%0.541-142%
Usd Book Value--44488045.40044418463.850+0%46477466.800-4%45581103.550-2%43700549.723+2%
Usd Book Value Change Per Share---0.007-0.004-39%-0.002-66%-0.001-82%0.005-235%
Usd Book Value Per Share--0.5140.513+0%0.537-4%0.523-2%0.500+3%
Usd Dividend Per Share----0%0.025-100%0.021-100%0.011-100%
Usd Eps---0.0010.003-126%0.005-114%0.006-113%0.003-126%
Usd Free Cash Flow--858924.600-7222.175+101%514340.125+67%-428727.035+150%-449428.813+152%
Usd Free Cash Flow Per Share--0.0100.000+101%0.006+67%-0.005+148%-0.007+168%
Usd Free Cash Flow To Equity Per Share--0.0100.000+102%-0.002+122%-0.011+208%-0.009+191%
Usd Market Cap58695389.558-12%65600729.50664671164.513+1%65833120.7540%65718890.9970%71324279.950-8%
Usd Price Per Share0.678-12%0.7580.748+1%0.7610%0.753+1%0.816-7%
Usd Profit---61860.500253205.925-124%437306.150-114%493405.795-113%244628.345-125%
Usd Revenue--2274931.4002440765.125-7%2828590.550-20%2741394.875-17%3394185.093-33%
Usd Total Gains Per Share---0.007-0.004-39%0.023-131%0.019-136%0.017-142%
 EOD+4 -4MRQTTM+17 -16YOY+8 -275Y+7 -2810Y+14 -22

3.2. Fundamental Score

Let's check the fundamental score of GenMont Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-237.209
Price to Book Ratio (EOD)Between0-11.319
Net Profit Margin (MRQ)Greater than0-0.027
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.124
Current Ratio (MRQ)Greater than13.180
Debt to Asset Ratio (MRQ)Less than10.123
Debt to Equity Ratio (MRQ)Less than10.155
Return on Equity (MRQ)Greater than0.15-0.002
Return on Assets (MRQ)Greater than0.05-0.001
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of GenMont Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.807
Ma 20Greater thanMa 5022.248
Ma 50Greater thanMa 10022.671
Ma 100Greater thanMa 20023.403
OpenGreater thanClose22.200
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  16,724-9,6797,045-6,13790824,55625,464-30,718-5,254
Net Income  13,845-5,6048,241-5,3542,88720,99123,878-25,893-2,015
Tax Provision  5,553-4,2731,280-5127683,4674,235-4,786-551
Net Income from Continuing Operations  11,171-5,4065,765-5,62514021,08921,229-25,932-4,703



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,653,181
Total Liabilities204,059
Total Stockholder Equity1,316,307
 As reported
Total Liabilities 204,059
Total Stockholder Equity+ 1,316,307
Total Assets = 1,653,181

Assets

Total Assets1,653,181
Total Current Assets465,509
Long-term Assets1,187,672
Total Current Assets
Cash And Cash Equivalents 55,595
Short-term Investments 272,707
Net Receivables 38,230
Inventory 88,118
Total Current Assets  (as reported)465,509
Total Current Assets  (calculated)454,650
+/- 10,859
Long-term Assets
Property Plant Equipment 1,060,101
Long-term Assets Other 6,050
Long-term Assets  (as reported)1,187,672
Long-term Assets  (calculated)1,066,151
+/- 121,521

Liabilities & Shareholders' Equity

Total Current Liabilities146,392
Long-term Liabilities57,667
Total Stockholder Equity1,316,307
Total Current Liabilities
Short Long Term Debt 2,235
Accounts payable 7,852
Other Current Liabilities 9,932
Total Current Liabilities  (as reported)146,392
Total Current Liabilities  (calculated)20,019
+/- 126,373
Long-term Liabilities
Long term Debt 20,112
Capital Lease Obligations Min Short Term Debt35,960
Long-term Liabilities Other 2,368
Long-term Liabilities  (as reported)57,667
Long-term Liabilities  (calculated)58,440
+/- 773
Total Stockholder Equity
Retained Earnings 37,909
Total Stockholder Equity (as reported)1,316,307
Total Stockholder Equity (calculated)37,909
+/- 1,278,398
Other
Capital Stock865,114
Common Stock Shares Outstanding 86,511
Net Invested Capital 1,338,654
Net Working Capital 319,117
Property Plant and Equipment Gross 1,060,101



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-06-302008-03-312007-06-302006-06-302004-06-302003-06-30
> Total Assets 
274,933
268,768
378,156
520,227
585,176
583,297
680,955
670,778
700,040
663,754
724,097
787,592
835,178
799,776
1,365,528
1,589,577
1,577,667
1,500,640
1,492,803
1,480,434
1,457,483
1,605,103
1,579,463
1,634,146
1,393,262
1,370,071
2,425,295
2,165,290
2,120,772
1,742,077
1,700,556
1,657,637
1,694,155
1,633,815
1,613,624
1,613,393
1,618,931
1,403,798
1,391,654
1,468,594
1,503,090
1,500,197
1,521,988
1,594,914
1,629,507
1,658,314
1,745,301
1,756,934
1,644,760
1,571,157
1,576,565
1,530,398
1,579,004
1,612,823
1,645,525
1,656,281
1,603,282
1,698,033
1,739,975
1,692,551
1,660,737
1,695,808
1,695,802
1,636,578
1,641,229
1,653,181
1,653,1811,641,2291,636,5781,695,8021,695,8081,660,7371,692,5511,739,9751,698,0331,603,2821,656,2811,645,5251,612,8231,579,0041,530,3981,576,5651,571,1571,644,7601,756,9341,745,3011,658,3141,629,5071,594,9141,521,9881,500,1971,503,0901,468,5941,391,6541,403,7981,618,9311,613,3931,613,6241,633,8151,694,1551,657,6371,700,5561,742,0772,120,7722,165,2902,425,2951,370,0711,393,2621,634,1461,579,4631,605,1031,457,4831,480,4341,492,8031,500,6401,577,6671,589,5771,365,528799,776835,178787,592724,097663,754700,040670,778680,955583,297585,176520,227378,156268,768274,933
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
454,272
448,491
492,447
542,739
524,049
536,939
1,267,729
1,176,640
1,113,738
1,177,685
1,046,239
776,271
683,762
701,332
630,824
610,826
595,940
607,514
580,949
522,524
580,792
598,580
584,853
500,459
521,502
525,076
503,704
453,355
465,509
465,509453,355503,704525,076521,502500,459584,853598,580580,792522,524580,949607,514595,940610,826630,824701,332683,762776,2711,046,2391,177,6851,113,7381,176,6401,267,729536,939524,049542,739492,447448,491454,2720000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
176,546
202,801
195,925
167,170
170,176
136,929
1,028,232
316,878
225,292
281,004
334,978
284,655
191,670
171,055
197,025
320,717
274,846
241,008
160,532
144,250
169,953
78,825
268,066
143,859
133,687
75,137
142,790
67,584
55,595
55,59567,584142,79075,137133,687143,859268,06678,825169,953144,250160,532241,008274,846320,717197,025171,055191,670284,655334,978281,004225,292316,8781,028,232136,929170,176167,170195,925202,801176,5460000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
126,236
89,300
123,132
179,422
201,685
208,710
65,730
660,776
701,600
718,040
573,926
334,800
334,800
377,350
281,710
136,350
190,280
197,962
263,070
203,005
251,776
364,814
204,948
251,924
267,256
327,626
228,258
243,550
272,707
272,707243,550228,258327,626267,256251,924204,948364,814251,776203,005263,070197,962190,280136,350281,710377,350334,800334,800573,926718,040701,600660,77665,730208,710201,685179,422123,13289,300126,2360000000000000000000000000000000000000
       Net Receivables 
6,121
7,538
70,510
77,643
106,073
110,326
109,983
92,262
109,113
102,291
119,061
137,110
114,869
107,129
124,564
102,436
65,444
49,258
50,995
41,575
37,804
42,145
36,934
57,308
72,722
48,120
51,493
57,966
50,315
32,418
51,143
51,618
86,843
87,790
96,026
115,190
100,553
84,408
87,922
108,580
122,063
79,182
115,869
124,311
147,146
123,881
66,394
57,723
63,246
72,014
57,267
61,032
48,454
46,441
74,577
63,272
60,441
55,062
42,150
64,477
47,606
51,762
44,533
50,012
43,880
38,230
38,23043,88050,01244,53351,76247,60664,47742,15055,06260,44163,27274,57746,44148,45461,03257,26772,01463,24657,72366,394123,881147,146124,311115,86979,182122,063108,58087,92284,408100,553115,19096,02687,79086,84351,61851,14332,41850,31557,96651,49348,12072,72257,30836,93442,14537,80441,57550,99549,25865,444102,436124,564107,129114,869137,110119,061102,291109,11392,262109,983110,326106,07377,64370,5107,5386,121
       Other Current Assets 
4,618
873
4,156
6,876
8,965
10,201
7,638
8,291
7,537
9,129
10,865
15,995
16,271
6,367
11,497
12,797
10,978
14,294
15,087
178,911
180,209
170,123
170,648
626,121
1,021,920
1,021,488
13,401
6,715
7,909
10,692
13,236
7,030
5,798
5,650
6,361
4,317
4,590
5,605
10,832
6,151
6,063
5,470
5,589
3,864
12,913
0
0
0
0
0
0
0
0
0
0
0
18,200
0
0
0
0
0
0
0
0
0
00000000018,2000000000000012,9133,8645,5895,4706,0636,15110,8325,6054,5904,3176,3615,6505,7987,03013,23610,6927,9096,71513,4011,021,4881,021,920626,121170,648170,123180,209178,91115,08714,29410,97812,79711,4976,36716,27115,99510,8659,1297,5378,2917,63810,2018,9656,8764,1568734,618
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
567,616
710,695
868,489
887,395
875,233
899,574
968,178
1,016,883
1,038,011
1,075,332
1,080,758
1,117,241
1,141,395
1,107,698
1,160,278
1,174,306
1,170,726
1,132,874
1,187,874
1,187,672
1,187,6721,187,8741,132,8741,170,7261,174,3061,160,2781,107,6981,141,3951,117,2411,080,7581,075,3321,038,0111,016,883968,178899,574875,233887,395868,489710,695567,6160000000000000000000000000000000000000000000000
       Property Plant Equipment 
125,353
118,272
99,787
107,757
154,999
165,907
168,785
165,513
167,555
165,935
171,672
169,422
172,022
169,748
169,628
166,056
161,315
158,583
149,460
144,558
139,689
132,414
128,969
126,148
122,605
120,177
1,055,173
1,038,277
1,037,827
919,997
914,688
904,524
894,842
884,579
877,343
874,511
873,688
866,697
860,535
866,372
867,485
865,254
858,834
149,835
241,712
352,684
426,711
496,303
622,096
750,548
744,313
763,156
822,452
922,684
960,901
997,637
1,020,380
1,045,112
1,066,906
1,041,512
1,110,236
1,113,233
1,103,992
1,060,112
1,074,268
1,060,101
1,060,1011,074,2681,060,1121,103,9921,113,2331,110,2361,041,5121,066,9061,045,1121,020,380997,637960,901922,684822,452763,156744,313750,548622,096496,303426,711352,684241,712149,835858,834865,254867,485866,372860,535866,697873,688874,511877,343884,579894,842904,524914,688919,9971,037,8271,038,2771,055,173120,177122,605126,148128,969132,414139,689144,558149,460158,583161,315166,056169,628169,748172,022169,422171,672165,935167,555165,513168,785165,907154,999107,75799,787118,272125,353
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
395,053
188,253
188,253
114,045
114,045
114,045
114,045
71,982
71,982
71,982
71,982
8,947
8,947
8,947
8,947
8,947
8,947
8,947
8,947
8,947
8,947
8,947
8,947
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000008,9478,9478,9478,9478,9478,9478,9478,9478,9478,9478,9478,94771,98271,98271,98271,982114,045114,045114,045114,045188,253188,253395,05300000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,938
37,317
37,925
27,745
40,350
38,776
34,307
37,650
41,853
51,191
41,496
36,295
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000036,29541,49651,19141,85337,65034,30738,77640,35027,74537,92537,31737,9380000000000000000000000000000000000000
       Intangible Assets 
28,570
25,012
0
0
0
0
0
0
0
13,087
13,087
13,087
13,087
13,087
13,087
13,087
13,087
13,087
13,087
13,087
13,087
165,747
165,747
13,507
13,458
13,385
658,190
437,214
426,347
341,594
330,882
324,432
313,345
260,920
249,773
238,463
228,076
14,202
13,771
13,347
12,922
12,517
12,086
279
400
341
282
224
165
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000016522428234140027912,08612,51712,92213,34713,77114,202228,076238,463249,773260,920313,345324,432330,882341,594426,347437,214658,19013,38513,45813,507165,747165,74713,08713,08713,08713,08713,08713,08713,08713,08713,08713,08713,08713,087000000025,01228,570
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,255
1,008
762
2,483
2,186
1,983
1,681
2,111
1,822
1,698
1,414
1,146
1,202
5,398
4,381
4,270
6,962
6,541
6,038
6,050
6,0506,0386,5416,9624,2704,3815,3981,2021,1461,4141,6981,8222,1111,6811,9832,1862,4837621,0081,2550000000000000000000000000000000000000000000000
> Total Liabilities 
9,308
12,628
44,186
35,355
43,503
51,366
71,360
62,092
122,151
66,392
88,417
105,074
166,125
104,216
627,657
581,193
726,400
601,332
585,252
579,419
624,348
579,064
563,169
751,248
529,398
505,707
1,591,023
1,355,699
1,356,618
144,756
128,481
124,189
143,362
133,430
119,358
117,594
130,093
124,143
114,827
111,294
129,349
129,414
143,416
125,402
95,252
95,604
129,557
247,424
119,132
123,044
128,646
176,473
121,803
130,951
141,334
145,322
131,317
173,648
157,801
210,875
166,109
198,590
247,920
215,055
172,334
204,059
204,059172,334215,055247,920198,590166,109210,875157,801173,648131,317145,322141,334130,951121,803176,473128,646123,044119,132247,424129,55795,60495,252125,402143,416129,414129,349111,294114,827124,143130,093117,594119,358133,430143,362124,189128,481144,7561,356,6181,355,6991,591,023505,707529,398751,248563,169579,064624,348579,419585,252601,332726,400581,193627,657104,216166,125105,07488,41766,392122,15162,09271,36051,36643,50335,35544,18612,6289,308
   > Total Current Liabilities 
7,186
10,942
42,645
34,368
43,356
51,224
71,220
61,952
122,039
66,280
88,302
104,959
166,027
104,118
127,568
88,636
231,941
104,971
100,466
579,419
624,348
579,064
563,169
750,558
528,711
504,956
1,129,016
906,819
923,504
132,580
116,550
112,156
130,978
121,098
107,013
105,691
118,176
112,250
102,918
101,423
119,617
119,916
131,142
121,732
91,655
91,761
92,484
212,142
82,384
88,307
92,911
141,062
85,343
94,957
105,828
110,330
96,633
139,169
131,491
186,776
142,239
160,777
210,274
177,127
114,277
146,392
146,392114,277177,127210,274160,777142,239186,776131,491139,16996,633110,330105,82894,95785,343141,06292,91188,30782,384212,14292,48491,76191,655121,732131,142119,916119,617101,423102,918112,250118,176105,691107,013121,098130,978112,156116,550132,580923,504906,8191,129,016504,956528,711750,558563,169579,064624,348579,419100,466104,971231,94188,636127,568104,118166,027104,95988,30266,280122,03961,95271,22051,22443,35634,36842,64510,9427,186
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,000
0
0
0
67
55
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000055670007,000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,000
0
0
0
67
55
0
0
0
1
0
0
88
0
0
0
30
396
132
0
0
0
2,280
2,235
2,2352,280000132396300008800100055670007,000000000000000000000000000000000000000000000
       Accounts payable 
1,894
2,918
3,641
4,864
3,305
3,518
4,526
5,707
6,542
7,418
11,851
11,055
9,396
10,781
13,779
6,806
11,644
10,209
6,429
9,433
7,956
10,531
6,283
8,348
7,707
4,606
43,919
49,389
66,835
37,680
34,920
31,785
45,148
30,151
24,406
24,446
29,021
24,581
23,111
24,087
29,717
25,141
23,433
4,229
6,070
7,687
2,490
6,739
5,799
7,703
9,760
7,994
7,488
7,386
8,002
11,502
5,481
11,390
12,937
6,075
4,424
14,365
8,070
8,953
4,205
7,852
7,8524,2058,9538,07014,3654,4246,07512,93711,3905,48111,5028,0027,3867,4887,9949,7607,7035,7996,7392,4907,6876,0704,22923,43325,14129,71724,08723,11124,58129,02124,44624,40630,15145,14831,78534,92037,68066,83549,38943,9194,6067,7078,3486,28310,5317,9569,4336,42910,20911,6446,80613,77910,7819,39611,05511,8517,4186,5425,7074,5263,5183,3054,8643,6412,9181,894
       Other Current Liabilities 
5,292
8,024
39,004
29,504
40,051
47,706
66,694
56,245
115,497
58,862
76,451
93,904
156,631
93,337
113,789
81,830
220,297
94,762
94,037
83,299
127,803
68,042
64,493
742,210
521,004
500,350
994,082
786,277
786,986
94,900
81,630
80,371
85,830
90,947
82,607
81,245
89,155
87,669
79,807
77,336
89,900
94,775
100,709
95,689
57,491
55,939
5,480
5,502
2,921
55,371
61,650
118,070
60,202
61,553
77,031
79,910
70,120
99,046
93,108
178,971
136,282
145,352
201,113
166,512
9,636
9,932
9,9329,636166,512201,113145,352136,282178,97193,10899,04670,12079,91077,03161,55360,202118,07061,65055,3712,9215,5025,48055,93957,49195,689100,70994,77589,90077,33679,80787,66989,15581,24582,60790,94785,83080,37181,63094,900786,986786,277994,082500,350521,004742,21064,49368,042127,80383,29994,03794,762220,29781,830113,78993,337156,63193,90476,45158,862115,49756,24566,69447,70640,05129,50439,0048,0245,292
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,073
35,282
36,748
34,737
35,735
35,411
36,460
35,994
35,506
34,992
34,684
34,479
26,310
24,099
23,870
37,813
37,646
37,928
58,057
57,667
57,66758,05737,92837,64637,81323,87024,09926,31034,47934,68434,99235,50635,99436,46035,41135,73534,73736,74835,28237,0730000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-7,000
0
0
0
34,008
33,546
33,128
32,653
33,530
33,033
34,818
34,330
33,822
33,379
33,056
32,733
22,339
21,921
21,495
34,545
34,409
35,262
34,811
35,960
35,96034,81135,26234,40934,54521,49521,92122,33932,73333,05633,37933,82234,33034,81833,03333,53032,65333,12833,54634,008000-7,000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,349
2,318
4,084
2,318
2,318
2,318
2,318
2,318
2,318
2,318
2,318
2,318
2,318
2,368
2,368
2,368
2,368
2,368
2,368
2,368
2,3682,3682,3682,3682,3682,3682,3682,3182,3182,3182,3182,3182,3182,3182,3182,3182,3184,0842,3182,3490000000000000000000000000000000000000000000000
> Total Stockholder Equity
265,625
256,140
297,364
465,402
517,572
507,197
581,837
580,077
552,882
570,712
607,492
652,390
642,258
666,913
706,871
750,259
621,233
674,613
677,165
671,354
620,868
1,026,039
1,016,294
882,898
863,864
864,364
834,272
809,591
764,154
1,597,321
1,572,075
1,533,448
1,550,793
1,500,385
1,494,266
1,495,799
1,488,838
1,279,655
1,276,827
1,323,788
1,339,807
1,337,171
1,345,039
1,436,366
1,462,773
1,490,710
1,542,065
1,404,998
1,396,365
1,384,962
1,385,569
1,292,601
1,307,838
1,329,276
1,353,386
1,362,210
1,324,289
1,376,440
1,430,581
1,334,520
1,349,182
1,351,325
1,303,698
1,284,876
1,330,680
1,316,307
1,316,3071,330,6801,284,8761,303,6981,351,3251,349,1821,334,5201,430,5811,376,4401,324,2891,362,2101,353,3861,329,2761,307,8381,292,6011,385,5691,384,9621,396,3651,404,9981,542,0651,490,7101,462,7731,436,3661,345,0391,337,1711,339,8071,323,7881,276,8271,279,6551,488,8381,495,7991,494,2661,500,3851,550,7931,533,4481,572,0751,597,321764,154809,591834,272864,364863,864882,8981,016,2941,026,039620,868671,354677,165674,613621,233750,259706,871666,913642,258652,390607,492570,712552,882580,077581,837507,197517,572465,402297,364256,140265,625
   Common Stock
300,000
300,000
405,520
449,054
449,054
449,054
501,854
501,854
492,964
492,964
492,964
492,964
540,794
540,794
540,794
540,794
540,794
540,794
526,133
526,133
526,133
609,119
609,119
609,119
609,119
609,119
609,119
609,119
609,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,119
889,344
889,344
889,344
889,344
878,484
863,414
863,414
863,714
863,714
863,714
863,714
863,714
863,714
863,714
863,714
863,714
0
0
00863,714863,714863,714863,714863,714863,714863,714863,714863,714863,414863,414878,484889,344889,344889,344889,344889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119889,119609,119609,119609,119609,119609,119609,119609,119609,119526,133526,133526,133540,794540,794540,794540,794540,794540,794492,964492,964492,964492,964501,854501,854449,054449,054449,054405,520300,000300,000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000-21,551-21,551-21,551-21,551-21,551-21,551-21,551-21,551-21,551-21,551-35,856-22,265000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,709
-5,540
-2,734
-10,158
3,013
8,555
6,370
-3,854
-574
9,278
1,128
-24,224
-31,530
-39,926
-50,666
-32,847
-11,489
-17,983
-24,579
-25,616
-17,833
13,010
238
6,784
-5,579
-987
-22,696
0
0
00-22,696-987-5,5796,78423813,010-17,833-25,616-24,579-17,983-11,489-32,847-50,666-39,926-31,530-24,2241,1289,278-574-3,8546,3708,5553,013-10,158-2,734-5,540-4,7090000000000000000000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue318,015
Cost of Revenue-106,823
Gross Profit211,192211,192
 
Operating Income (+$)
Gross Profit211,192
Operating Expense-310,290
Operating Income7,725-99,098
 
Operating Expense (+$)
Research Development46,863
Selling General Administrative156,604
Selling And Marketing Expenses0
Operating Expense310,290203,467
 
Net Interest Income (+$)
Interest Income8,524
Interest Expense-973
Other Finance Cost-0
Net Interest Income7,551
 
Pretax Income (+$)
Operating Income7,725
Net Interest Income7,551
Other Non-Operating Income Expenses0
Income Before Tax (EBT)28,1637,725
EBIT - interestExpense = -973
32,991
33,964
Interest Expense973
Earnings Before Interest and Taxes (EBIT)029,136
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax28,163
Tax Provision-5,732
Net Income From Continuing Ops22,43122,431
Net Income32,991
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-7,551
 

Technical Analysis of Genmont
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Genmont. The general trend of Genmont is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Genmont's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GenMont Biotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 22.95 < 23.30 < 23.30.

The bearish price targets are: 21.60 > 21.40 > 21.40.

Tweet this
GenMont Biotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GenMont Biotech Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GenMont Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GenMont Biotech Inc. The current macd is -0.15294623.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genmont price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Genmont. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Genmont price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GenMont Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartGenMont Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GenMont Biotech Inc. The current adx is 21.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Genmont shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
GenMont Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GenMont Biotech Inc. The current sar is 22.91.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GenMont Biotech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GenMont Biotech Inc. The current rsi is 44.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
GenMont Biotech Inc Daily Relative Strength Index (RSI) ChartGenMont Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GenMont Biotech Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Genmont price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
GenMont Biotech Inc Daily Stochastic Oscillator ChartGenMont Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GenMont Biotech Inc. The current cci is -29.11423637.

GenMont Biotech Inc Daily Commodity Channel Index (CCI) ChartGenMont Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GenMont Biotech Inc. The current cmo is -10.48592808.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
GenMont Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartGenMont Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GenMont Biotech Inc. The current willr is -54.83870968.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Genmont is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GenMont Biotech Inc Daily Williams %R ChartGenMont Biotech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GenMont Biotech Inc.

GenMont Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GenMont Biotech Inc. The current atr is 0.40403683.

GenMont Biotech Inc Daily Average True Range (ATR) ChartGenMont Biotech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GenMont Biotech Inc. The current obv is 19,130,976.

GenMont Biotech Inc Daily On-Balance Volume (OBV) ChartGenMont Biotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GenMont Biotech Inc. The current mfi is 69.70.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
GenMont Biotech Inc Daily Money Flow Index (MFI) ChartGenMont Biotech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GenMont Biotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

GenMont Biotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GenMont Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.807
Ma 20Greater thanMa 5022.248
Ma 50Greater thanMa 10022.671
Ma 100Greater thanMa 20023.403
OpenGreater thanClose22.200
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Genmont with someone you think should read this too:
  • Are you bullish or bearish on Genmont? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Genmont? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GenMont Biotech Inc

I send you an email if I find something interesting about GenMont Biotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about GenMont Biotech Inc.

Receive notifications about GenMont Biotech Inc in your mailbox!